Cargando…
Management of possible serious bacterial infection in young infants where referral is not possible in the context of existing health system structure in Ibadan, South-west Nigeria
INTRODUCTION: Neonatal infections contribute substantially to infant mortality in Nigeria and globally. Management requires hospitalization, which is not accessible to many in low resource settings. World Health Organization developed a guideline to manage possible serious bacterial infection (PSBI)...
Autores principales: | Ayede, Adejumoke Idowu, Ashubu, Oluwakemi Oluwafunmi, Fowobaje, Kayode Raphael, Aboubaker, Samira, Nisar, Yasir Bin, Qazi, Shamim Ahmad, Bahl, Rajiv, Falade, Adegoke Gbadegesin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009401/ https://www.ncbi.nlm.nih.gov/pubmed/33784321 http://dx.doi.org/10.1371/journal.pone.0248720 |
Ejemplares similares
-
Costs and cost-effectiveness of management of possible serious bacterial infections in young infants in outpatient settings when referral to a hospital was not possible: Results from randomized trials in Africa
por: Garg, Charu C., et al.
Publicado: (2021) -
Clinical signs of possible serious infection and associated mortality among young infants presenting at first-level health facilities
por: Nisar, Yasir Bin, et al.
Publicado: (2021) -
Care seeking behaviour and aspects of quality of care by caregivers for children under five with and without pneumonia in Ibadan, Nigeria
por: Kirolos, Amir, et al.
Publicado: (2018) -
Prevalence of clinical signs of possible serious bacterial infection and mortality associated with them from population-based surveillance of young infants from birth to 2 months of age
por: Puri, Dhruv, et al.
Publicado: (2021) -
An open randomized clinical trial in comparing two artesunate-based combination treatments on Plasmodium falciparum malaria in Nigerian children: artesunate/sulphamethoxypyrazine/pyrimethamine (fixed dose over 24 hours) versus artesunate/amodiaquine (fixed dose over 48 hours)
por: Ayede, Idowu Adejumoke, et al.
Publicado: (2010)